Sabrina Serani is a senior editor for Targeted Oncology.
An Aggressive Approach to Ovarian Cancer Treatment?
Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.
Dostarlimab Plus Chemo Betters OS in Endometrial Cancer
The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.
INT230-6 Shows Promising Efficacy, Safety in Sarcomas
According to findings presented at the Connective Tissue Oncology Society Annual Meeting, INT230-6 enhanced overall survival and disease control rates in relapsed, refractory, and metastatic sarcomas.
Pembrolizumab Improves OS in RCC Following Nephrectomy
In the KEYNOTE-564 trial, patients with renal cell carcinoma who had a nephrectomy achieved improved overall survival rates vs placebo when treated with adjuvant pembrolizumab.
FDA Accepts NDA for Tovorafenib in Pediatric Low-Grade Glioma
The FDA accepted the new drug application and granted priority review to tovorafenib with a Prescription Drug User Fee Act target date of April 30, 2024.
ZR-CHOP Shows Promise in Treatment-Naïve DLBCL
A phase 2 clinical trial has demonstrated the potential of zanubrutinib combined with R-CHOP for the treatment of untreated diffuse large B-cell lymphoma with extranodal involvement.
SLS009 Earns FDA Fast Track Designation for R/R PTCL
SLS009 showed promising efficacy in a phase 1 trial and now has been granted a fast track designation by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Do Race and Ethnicity Affect Response to CAR T-Cell Therapy?
While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Tisotumab Vedotin Shows Potential in Cervical Cancer With Disease Progression
In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
ONCT-534 Gains FDA Fast Track Designation in mCRPC
The investigational agent is undergoing evaluation in a phase 1/2 trial for the treatment of relapsed or refractory metastatic castration-resistant prostate cancer resistant to androgen receptor pathway inhibitors.
Behind the FDA Approval of Ivosidenib in IDH1-Mutated MDS
In an interview with Targeted Oncology, Courtney DiNardo, MD, MSCE, discussed what oncologists should know about ivosidenib and the drug’s potential in treating hematologic malignancies.
FDA Accepts BLA Resubmission of N-803/BCG for NMIBC
After issuing a complete response letter in May 2023, the FDA has now accepted the resubmission of the biologics license application of a drug regimen for the treatment of non-muscle-invasive bladder cancer.
Identifying the Link Between CAR T and Cardiac Events
A study published in the Journal of the American College of Cardiology found that chimeric antigen receptor T-cell therapy was associated with fewer major cardiac events than previously thought.
FDA Expands Entrectinib Approval in Pediatric Patients With NTRK+ Solid Tumors
The FDA has expanded the indication of entrectinib for the treatment of pediatric patients 1 month and older with solid tumors harboring an NTRK gene fusion.
Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC
Longer follow-up data from the KRYSTAL-7 trial support the initiation of a phase 3 trial evaluating concurrent adagrasib with pembrolizumab in treatment-naïve patients with KRASG12C-mutated non–small cell lung cancer and PD-L1 ≥50%.
Azacitidine, Venetoclax, Ruxolitinib Shows Encouraging Responses in MPNs
Findings from a 5-patient study evaluating azacitidine, venetoclax, and ruxolitinib for the treatment of myeloproliferative neoplasms shows promise. More research is warranted.
Subcutaneous Nivolumab Noninferior to IV Version in ccRCC
The phase 3 CheckMate -67T trial found that a subcutaneous formulation of nivolumab met its co-primary pharmacokinetic end points compared with the intravenous formulation in clear cell renal cell carcinoma.
Nivolumab/Chemotherapy Regimen Shows EFS Benefits in NSCLC
Neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab demonstrated improvements in event-free survival, pathologic complete response, and major pathologic response in non–small cell lung cancer.
Study Supports Daratumumab Use in R/R Multiple Myeloma
While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.
Improvements in NSCLC With Neoadjuvant Nivolumab Observed
Findings from a 3-year follow-up of the Checkmate-816 trial demonstrated promising results with nivolumab and platinum-based chemotherapy, including improvements in event-free survival.
Nivolumab/Chemotherapy Leads to OS, PFS Improvements in UC
Findings from the CheckMate-901 trial demonstrated improvements for the treatment of patients with urothelial carcinoma who received a combination of nivolumab and chemotherapy followed by nivolumab monotherapy.
Neoadjuvant Daromun Meets Primary End Point of RFS in Melanoma
A trial of intratumoral daromun and surgical resection for the treatment of patients with locally advanced, fully resectable melanoma, showed a clinically meaningful improvement compared with surgery alone.
Trials of Nanrilkefusp Alfa Discontinued in Advanced Solid Tumors
Nanrilkefusp alfa did not show sufficient efficacy as a monotherapy or in combination with anti-PD-1 treatments to warrant further development.
Dovitinib Companion Diagnostic Shows Results in RCC
The tool shows promise to predict a patient’s response to dovitinib to better inform treatment options for patients with renal cell carcinoma and other solid tumors.
FDA Grants Priority Review to Osimertinib Plus Chemotherapy for NSCLC
The FDA has accepted a supplemental new drug application and granted priority review for osimertinib with chemotherapy for the treatment of patients with locally advanced or metastatic non–small cell lung cancer.
TBI-1301 Immunotherapy Shows Improvement in Synovial Sarcoma Treatment
TBI-1301 demonstrated superior efficacy compared with standard-of-care treatment in patients with synovial sarcoma. Further research is warranted.
Anlotinib Shows PFS Improvements in Patients With Thyroid Cancer
Patients had longer median progression-free survival rates with anlotinib vs with placebo in a phase 2 trial, but overall survival data were still immature.
Novel Regimen Shows Promise for Multiple Myeloma, Myelofibrosis
Researchers used split-dose busulfan, fludarabine, and post-transplant cyclophosphamide on 6 patients in a phase 2 study, and further research is warranted.
Tislelizumab Could Be a First-Line Treatment for HCC
Tislelizumab met its primary end point of overall survival and exceeded that of sorafenib in patients with unresectable hepatocellular carcinoma.
BXCL701 and Pembrolizumab Combo Delivers OS Improvements in SCNC
In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.
2 Clarke Drive Cranbury, NJ 08512